A complete Growth financial model for Healthcare Biotech startups. Revenue model, unit economics, hiring plan, cash flow projections, and funding scenarios — structured for investor review.
Projection Horizon
3 years with LTM actuals (trailing twelve months)
Model Tabs
7 core tabs
Format
Excel + Google Sheets
EBITDA generation, free cash flow conversion, and exit multiple positioning. Growth-stage investors are sizing the return on their investment against exit scenarios.
Healthcare models must show revenue cycle efficiency separately from clinical cost. Investors want to see AR days trend, denial rate trend, and payer mix shift over time — not just blended revenue per patient.
Reimbursement-driven revenue model with payer mix, reimbursement rates, and billing collection efficiency. Model patient volume ramp separately from revenue per patient as payer mix shifts.
Growth stage models require GAAP financial statements as the foundation. All projections must reconcile to audited financials. Quality-of-earnings adjustments should be clearly documented with investor-friendly presentation.
Include IPO, strategic acquisition, and secondary scenarios with implied multiples based on comparable company trading and transaction comps.
A Growth Healthcare Biotech financial model should cover 3 years with LTM actuals (trailing twelve months) of projections with these tabs: LTM Financial Summary, EBITDA Bridge, Free Cash Flow Model, Working Capital Analysis, Capital Structure and Debt Schedule, Scenario Analysis (exit scenarios), Comparable Company Benchmarking. EBITDA generation, free cash flow conversion, and exit multiple positioning. Growth-stage investors are sizing the return on their investment against exit scenarios.
Reimbursement-driven revenue model with payer mix, reimbursement rates, and billing collection efficiency. Model patient volume ramp separately from revenue per patient as payer mix shifts. The key revenue drivers are: Patient volume x reimbursement rate by payer class; Commercial payer revenue (higher reimbursement); Medicare/Medicaid revenue (standardized rates); Enterprise health system contract revenue.
Healthcare Biotech unit economics at the Growth stage should include: Revenue per patient by payer type; Cost to serve per patient (clinical + overhead); Contribution margin per patient at break-even; Patient acquisition cost via provider referral; Prior authorization denial rate and cost impact. Healthcare models must show revenue cycle efficiency separately from clinical cost. Investors want to see AR days trend, denial rate trend, and payer mix shift over time — not just blended revenue per patient.
Growth stage models require GAAP financial statements as the foundation. All projections must reconcile to audited financials. Quality-of-earnings adjustments should be clearly documented with investor-friendly presentation. Start with the smallest unit of your business (one customer, one transaction, one seat) and build up from there. Every assumption should have a source or benchmark you can defend in an investor meeting.
Include IPO, strategic acquisition, and secondary scenarios with implied multiples based on comparable company trading and transaction comps.
Get the Healthcare Biotech Growth financial model as a pre-built Excel and Google Sheets template. Assumptions dashboard, revenue model, unit economics, and cash flow — ready to customize.
Includes Excel file, Google Sheets version, and model documentation guide